Scienture Holdings, Inc.
SCNX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.93
KIRA · Stoqly’s AI analyst, in plain words
- Scienture Holdings, Inc. had $0.4M of revenue in fiscal 2025, up 216.0% on the year before. Over five years, revenue changed −52.1% a year on average.
- Its operating margin was −9,868.1%, up 894.0 pts: of every 100 in sales, about −9,868 is left after running the business.
- Scienture Holdings, Inc. lost $41.5M in fiscal 2025.
Market cap
$116M
P/E
—
Revenue
$0.4M
Net income
−$41.5M
Free cash flow
—
Operating margin
−9,868.1%
Scienture Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+216.0%
Yes. Sales grew 216.0% last year.
Does it make a profit?
−9,618.2%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Scienture Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Scienture Holdings, Inc.
- CIK
- 0001382574
Scienture Holdings, Inc. · SCNX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $9.9M | $10.3M | $1.4M | $0.1M | $0.4M |
| Revenue growth | −42.2% | 3.6% | −86.7% | −90.0% | 216.0% |
| Gross margin | 48.0% | 53.8% | 3.6% | 4.4% | 76.8% |
| Operating margin | −53.5% | −28.4% | −322.4% | −10,762.1% | −9,868.1% |
| Net income | −$5.3M | −$3.5M | −$17.8M | $9.1M | −$41.5M |
| Net margin | −53.8% | −33.9% | −1,308.4% | 6,636.7% | −9,618.2% |
| Diluted EPS | −$0.65 | −$6.13 | −$23.35 | $2.48 | −$2.70 |
| Cash | |||||
| Cash from operations | −$2.6M | −$1.5M | −$2.2M | −$14.3M | −$13.4M |
| Capital expenditure | $0.0M | — | — | $0.0M | — |
| Free cash flow | −$2.6M | — | — | −$14.3M | — |
| FCF margin | −26.2% | — | — | −10,451.8% | — |
| Dividends paid | — | — | — | $14.9M | — |
| Share count change | 5.6% | −93.0% | 320.3% | 53.4% | 320.1% |
| Debt and strength | |||||
| Cash and short-term investments | $3.1M | $1.1M | $0.0M | $0.3M | $6.7M |
| Debt incl. finance leases | — | — | — | $2.9M | — |
| Deposits | — | — | — | — | $1.2M |
| Shareholders' equity | $3.8M | $0.8M | $0.5M | $79.1M | $70.1M |
| Current ratio | 4.7x | 1.0x | 0.2x | 0.8x | 2.9x |
| Interest coverage | −224.3x | −8.7x | −3.7x | −11.0x | −10.4x |
| Returns and quality | |||||
| Return on capital | — | — | — | −14.2% | — |
| Return on equity | −85.4% | −153.2% | −2,733.6% | 22.8% | −55.6% |
| Return on tangible equity | −141.0% | −455.0% | — | — | — |
| Piotroski F-score | 2 | 4 | 1 | 4 | 4 |
| Altman Z'' | −9.4 | −22.5 | −15.6 | 1.0 | −0.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Scienture Holdings, Inc. · SCNX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.93 a share, the company is worth $116M.
Source: SEC EDGAR XBRL filings (CIK 0001382574). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.